Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody-associated Vasculitis in Canada, 2010-2020

J Rheumatol. 2021 Sep 1:jrheum.210537. doi: 10.3899/jrheum.210537. Online ahead of print.ABSTRACTRituximab (RTX) is the only biologic approved to date for the treatment of antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV).1,2,3 The Canadian Vasculitis Research Network (CanVasc) has recommended RTX as first-line therapy for remission induction,4 and recently, as the preferred maintenance agent in severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).5.PMID:34470792 | DOI:10.3899/jrheum.210537
Source: Journal of Rheumatology - Category: Rheumatology Authors: Source Type: research